Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Trends in Immunology   Volumes    Volume 21 
Modulation of IL-17/IL-23 axis by chloroform fraction of Boerhavia erecta L.: a potential route for treating autoimmune disorders
Suresh Kumar Karri, Angappan Sheela
Pages: 109 - 121
Number of pages: 13
Current Trends in Immunology
Volume 21 

Copyright © 2020 Research Trends. All rights reserved

In view of remarkable similarities between two autoimmune disorders, rheumatoid arthritis and type 1 diabetes, and associated long-term adverse effects of pharmaceutical drugs in the treatment of such chronic metabolic disorders, herbal drugs are being targeted. This study evaluated immuno-modulatory activity of chloroform fraction of standardized hydro-alcoholic extract of root and stem parts of Boerhavia erecta L. (BE) containing 1-(4-hydroxytridecyloxy) pentadecan-4-ol by gene expression, in vitro and in vivo methods. A new bioactive compound, 1-(4-hydroxytridecyloxy) pentadecan-4-ol, hitherto unreported, was isolated from BE. The isolated compound was characterized by NMR and FTIR and the chloroform fraction containing the bioactive compound was subjected to in vivo anti-inflammatory and antidiabetic studies. Carrageanan-induced paw edema and cotton pellet granuloma in Wistar rats were considered as acute and chronic inflammatory models, respectively, with 5 groups (6 animals per group) in each study. After oral glucose tolerance test (OGTT), streptozotocin (STZ)-induced diabetic rat model with 6 groups of 6 animals each was used for antidiabetic study. In in vitro studies on RAW cell lines, the cell lines were stimulated with Lipopolysaccharide (LPS) and then treated with interleukin (IL) IL-23, IL-1β and IL-6 that were co-cultured both in the presence and absence of different doses (10 mg, 20 mg and 40 mg) of chloroform fraction of BE extract and finally the inhibition of IL-17 expression was recorded. The chloroform fraction having 1-(4-hydroxytridecyloxy) pentadecan-4-ol, at 40 mg/kg body weight, was effective as an antidiabetic and anti-inflammatory agent and exhibited statistical significance with that of control animal groups (p < 0.01). The study showed the inhibition of IL-17 significantly (p < 0.0001) in the presence of IL-23 and other cytokines. These immuno-modulatory activities are probably through IL-17/IL-23 axis which needs to be to be further confirmed by human clinical trials targeting at least two autoimmune diseases.
View Full Article  


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms